Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD30 Purified

Anti-Hu CD30 Purified

Regulatory status

RUO

Antigen

CD30

Clone

MEM-268

Format

Purified

Reactivity

Human

Application

FC (QC tested), IHC(P)

Variant

0.1 mg

11-455-C100

In stock

154.00 USD

0.025 mg

11-455-C025

Delivery 1 week

77.00 USD

Variant

0.1 mg

11-455-C100

In stock

154.00 USD

0.025 mg

11-455-C025

Delivery 1 week

77.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG2a kappa

Specificity

The antibody MEM-268 recognizes extracellular part of CD30 (Ki-1 antigen), a 105 kDa single chain glycoprotein expressed on Hodgkin's and Reed-Sternberg cells; it is also found in Burkitt's lymphomas, virus-infected T and B lymphocytes, and on normal B and T lymphocytes after activation (T lymphocytes that produce Th2-type cytokines and on CD4+/CD8+ T lymphocytes that co-express CD45RO and the IL4 receptor).

Application

FC (QC tested), IHC(P)

Application details

Flow cytometry: Recommended dilution: 5 μg/ml.
Immunohistochemistry (paraffin sections): Recommended dilution: 5 μg/ml, positive tissue: thymus.

Reactivity

Human

Immunogen

Expression vector containing CD30 cDNA (booster suspension of THP-1 cell line)

Concentration

1 mg/ml

Preparation

Purified by protein-A affinity chromatography.

Formulation

Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

Ki-1, TNFRSF8, CD30L receptor, D1S166E

Antigen description

CD30 is a type I transmembrane glycoprotein of the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkins and Reed-Sternberg cells using monoclonal antibody Ki-1. The ligand for CD30 is CD30L (CD153). The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. CD30 has a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas. CD30 acts as a costimulatory molecule in thymic negative selection. In addition to its expression on Hodgkin's and Reed-Sternberg cells, CD30 is also found in some non-Hodgkin's lymphomas (including Burkitt's lymphomas), virus-infected T and B cells, and on normal T and B cells after activation. In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and the IL4 receptor. Soluble form of CD30 (sCD30) serves as a marker reflecting Th2 immune response.

Entrez Gene ID 943

UniProt ID P28908

Flow cytometry analysis (surface staining) of K562 cells with anti-human CD30 (MEM-268) purified, GAM APC.

General references:

Wright CW, Rumble JM, Duckett CS: CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. J Biol Chem. 2007 Apr;282(14):10252-62.
PubMed

Zeiser R, Nguyen VH, Hou JZ, Beilhack A, Zambricki E, Buess M, Contag CH, Negrin RS: Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. Blood. 2007 Mar 1;109(5):2225-33.
PubMed

Kusanovic JP, Romero R, Hassan SS, Gotsch F, Edwin S, Chaiworapongsa T, Erez O, Mittal P, Mazaki-Tovi S, Soto E, Than NG, Friel LA, Yoon BH, Espinoza J: Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies. J Matern Fetal Neonatal Med. 2007 Aug 28:1-12
PubMed

Bekiaris V, Withers D, Glanville SH, McConnell FM, Parnell SM, Kim MY, Gaspal FM, Jenkinson E, Sweet C, Anderson G, Lane PJ: Role of CD30 in B/T segregation in the spleen. J Immunol. 2007 Dec 1;179(11):7535-43.
PubMed

Polte T, Behrendt AK, Hansen G: Direct evidence for a critical role of CD30 in the development of allergic asthma. J Allergy Clin Immunol. 2006 Oct;118(4):942-8.
PubMed

Kennedy MK, Willis CR, Armitage RJ: Deciphering CD30 ligand biology and its role in humoral immunity. Immunology. 2006 Jun;118(2):143-52.
PubMed

Fischer M, Harvima IT, Carvalho RF, Möller C, Naukkarinen A, Enblad G, Nilsson G: Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest. 2006 Oct;116(10):2748-56.
PubMed

Blazar BR, Levy RB, Mak TW, Panoskaltsis-Mortari A, Muta H, Jones M, Roskos M, Serody JS, Yagita H, Podack ER, Taylor PA: CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease. J Immunol. 2004 Sep 1;173(5):2933-41.
PubMed

Product specific references:

Pavlov I, Martins TB, Delgado JC: Development and validation of a fluorescent microsphere immunoassay for soluble CD30 testing. Clin Vaccine Immunol. 2009 Sep;16(9):1327-31.
PubMed